San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

Citi analyst Joanne Wuensch maintained a Buy rating on Dexcom (DXCM – Research Report) today. The company’s shares closed yesterday at ...

The stock's fall snapped a two-day winning streak.

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The firm increased its portfolio allocation in DXCM by 15.90% over the last quarter. Capital Research Global Investors holds 14,372K shares representing 3.68% ownership of the company. In its ...

In early trading on Thursday, shares of DexCom (DXCM) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.9%. Year to date, DexCom has lost about 8.1% of ...

Explore DexCom stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DXCM. FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US ...